Investigating how RNA methylation affects kidney cancer progression
Official title: RNA methylation as a novel effector of SETD2 in kidney cancer
Funded at Mayo Clinic Rochester · NIH-11061848 · Data updated 2026-11-12
This study is looking at how changes in the SETD2 gene affect kidney cancer, specifically clear cell renal cell carcinoma, to find new ways to treat it better and help patients with personalized therapies.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $188,636 |
| NIH project number | 5R21CA283539-02 |
| Project ID | NIH-11061848 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with clear cell renal cell carcinoma, particularly those with mutations in the SETD2 gene.
✕Less likely to help
Patients with other types of kidney cancer or those without actionable mutations in SETD2 may not benefit from this research.
What this research studies
This research focuses on clear cell renal cell carcinoma (ccRCC), a common and deadly form of kidney cancer. It aims to understand the role of the SETD2 gene, which is often mutated in ccRCC, and how these mutations impact RNA methylation and gene expression. By studying the mechanisms of SETD2 loss, the research seeks to identify new pathways that drive cancer growth and metastasis, potentially leading to more effective treatments. Patients may benefit from insights that could inform personalized therapies targeting these specific genetic alterations.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies for kidney cancer that are tailored to the genetic profile of individual tumors.
How similar studies have gone: Previous research has shown promising results in targeting epigenetic alterations in cancer, suggesting that this approach may yield significant insights and advancements.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Robertson, Keith D — Mayo Clinic Rochester
- Study coordinator: Robertson, Keith D
Related research
Other NIH-funded projects on the same topics.
-
Maximizing anti-tumor immune responses in kidney cancer
A cutting-edge program at UT Southwestern aims to speed up better immunotherapy options for kidney cancer by studying how to activate both innate and adaptive immune responses.
-
Kidney Cancer Career Enhancement Program (CEP) at DF/HCC
A career-boosting program supports junior investigators studying kidney cancer to help them advance in basic, translational, and clinical work.
-
Kidney Cancer Development Program at DF/HCC
A funded program at Dana-Farber/Brigham and Women’s Kidney Cancer Center supports new ideas from researchers to improve understanding and treatment of kidney cancer.
-
Personalized antigens for kidney cancer therapy
This grant explores identifying and targeting tumor-specific antigens in kidney cancer to develop more effective, personalized immunotherapies.
-
Optimizing Anti-PD1 Therapy for High-Risk and Metastatic Kidney Cancer
A large cancer research grant is testing how best to use anti-PD-1 therapy to help people with high-risk and metastatic kidney cancer live longer and with fewer side effects.
-
Targeting the HIF2 Pathway in Kidney Cancer
A cancer treatment program aims to see if a drug called belzutifan can help people with a specific kind of kidney cancer whose growth is driven by the HIF2 pathway.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.